Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

ReCOUP is a multicenter clinical study designed to evaluate the efficacy of upadacitinib (Rinvoq®) in patients with ulcerative colitis whose disease has become active again despite maintenance treatment with upadacitinib 30 mg. This study involves adult patients aged 18 to 64 years with active ulcerative colitis, who are being treated with upadacitinib and are not participating in another interventional clinical trial. Participation in this study will depend on the patients' response to treatment during the 52-week maintenance period. Several follow-up visits will be scheduled throughout the study according to a timetable defined by the protocol, and additional visits may be arranged if necessary depending on patients' health status.

NCT Number	NCT07700446
Lead Sponsor	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Conditions	Ulcerative Colitis (UC)
Enrollment	100 participants
Start Date	2026-11-15
Primary Completion	2029-11 (estimated)
Study Completion	2030-04 (estimated)
Updated on ClinicalTrials.gov	2026-07-31